Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Targeted therapies and clinical trial enrollment

11 evidence topics · 10 sources

Selumetinib plus dacarbazine versus placebo plus dacarbazine: phase 3 SUMIT trial of 129 participants

“The Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) study was a phase III, double-blind trial” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“patients with metastatic uveal melanoma and no prior systemic therapy were randomly assigned (3:1) to selumetinib (75 mg twice daily) plus dacarbazine (1,000 mg/m2 intravenously on day 1 of every 21-day cycle) or placebo plus dacarbazine.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 129 patients were randomly assigned to receive selumetinib plus dacarbazine (n = 97) or placebo plus dacarbazine (n = 32).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In the selumetinib plus dacarbazine group, 82 patients (85%) experienced a PFS event, compared with 24 (75%) in the placebo plus dacarbazine group (median, 2.8 v 1.8 months); the hazard ratio for PFS was 0.78 (95% CI, 0.48 to 1.27; two-sided P = .32).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“In patients with metastatic uveal melanoma, the combination of selumetinib plus dacarbazine had a tolerable safety profile but did not significantly improve PFS compared with placebo plus dacarbazine.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote